arrow
M

Michael Poledniczek

Medical University of Vienna
H指数:9
被引数:253

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis

CMR衍生的骨骼肌T1时间和细胞外容积作为心脏淀粉样变的新的诊断标志物

2026-03-300
OAAI
The Neutrophil-Lymphocyte Ratio Is Associated with Cardiac Magnetic Resonance Imaging-Derived Myocardial Fibrosis

中性粒细胞-淋巴细胞比值与心脏磁共振成像衍生的心肌纤维化相关

2026-02-120
OA
Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features

心脏淀粉样变性中的冠状动脉疾病:患病率、临床相关性及心脏磁共振成像特征

2025-12-130
OAAI
Impact of disease-modifying therapy on [99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence

人工智能赋能的疾病修饰性疗法对转甲状腺素蛋白心脏淀粉样变性[99mTc]Tc-DPD SPECT/CT标志物的影响

2025-11-290
OAAI
Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy

在行骨闪烁显像的佩鲁吉尼1级患者中,胸部SPECT/CT成像的附加诊断价值

2025-11-120
OAAI
Left atrial appendage thrombi despite oral anticoagulation in transthyretin amyloid cardiomyopathy patients undergoing electrical cardioversion for atrial fibrillation or − flutter

尽管接受了口服抗凝治疗,转甲状腺素蛋白淀粉样变性心肌病患者在为心房颤动或心房扑动进行电复律时仍出现左心耳血栓。

2025-10-080
OAAI
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of cardiovascular outcome trials

转甲状腺素蛋白淀粉样变性心肌病中的淀粉样蛋白特异性药物治疗:心血管结局试验的系统评价和Meta分析

2025-08-300
OAAI
Association between CMR-derived hepatic T1-time, tricuspid regurgitation and survival

CMR衍生的肝T1时间、三尖瓣反流与生存之间的关联

2025-08-080
OA
Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis

使用心脏磁共振成像对接受tafamidis治疗的转甲状腺素蛋白淀粉样变性患者的血清外容积进行连续量化

2025-07-160
OA